We are live on ! Find out more
AEON.WS

AEON Biopharma Inc
AEON.WS

Delisted

AEON.WS was delisted on the 26th of April, 2024.

Back to rankings

50 hedge funds and large institutions have $6.98M invested in AEON Biopharma Inc in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 55 → 50 (-5)

17% less capital invested

Capital invested by funds: $8.42M → $6.98M (-$1.44M)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
50
Holders Change
-5
Holders Change %
-9.09%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
7
Closed
8
Calls
$1.04M
Puts
–
Net Calls
+$1.04M
Net Calls Change
-$67K

Top Buyers

Rank Fund Capital Flow
1
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$153K
2
AC
Aristeia Capital
Connecticut
+$138K
3
CF
Cantor Fitzgerald
New York
+$22K
4
Nomura Holdings
Nomura Holdings
Japan
+$12.3K
5
CC
Centiva Capital
New York
+$6.88K

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$87K
2
Blackstone Inc
Blackstone Inc
New York
-$85K
3
ICMH
Integrity Capital Management (HK)
Hong Kong
-$35K
4
RA
Ramius Advisors
New York
-$35K
5
WAM
Wolverine Asset Management
Illinois
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$22K – – –
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$21K – – –
SC
28
Sculptor Capital
New York
$21K +$6.88K +16,666 +33%
GPCM
29
Granite Point Capital Management
Massachusetts
$20K – – –
DCM
30
Dupont Capital Management
Delaware
$16K – – –
FCM
31
Farallon Capital Management
California
$16K – – –
AA
32
AQR Arbitrage
Connecticut
$15K – – –
FIG
33
Fortress Investment Group
New York
$14K -$1.59K -3,861 -8%
AR
34
Advisory Research
Illinois
$14K – – –
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$10K – – –
ESCM
36
Echo Street Capital Management
New York
$10K – – –
MCM
37
Moore Capital Management
New York
$10K – – –
ACA
38
Arena Capital Advisors
California
$9K -$22K -53,285 -64%
Nomura Holdings
39
Nomura Holdings
Japan
$9K +$12.3K +29,833 New
PAMP
40
Polar Asset Management Partners
Ontario, Canada
$8K -$3.71K -9,000 -25%
EH
41
EMG Holdings
Connecticut
$8K – – –
CC
42
Centiva Capital
New York
$8K +$6.88K +16,666 +166%
OMC
43
Old Mission Capital
Illinois
$4K -$497 -1,205 -7%
JP Morgan Chase
44
JP Morgan Chase
New York
$4K – – –
RCM
45
Rivernorth Capital Management
Florida
$4K – – –
TCM
46
Tegean Capital Management
New York
$4K – – –
AA
47
Ancora Advisors
Ohio
$2K – – –
6CM
48
683 Capital Management
New York
$1K – – –
UBS Group
49
UBS Group
Switzerland
$1K – – –
UOC
50
UBS O'Connor
Illinois
– -$87K -171,253 Closed
1
2
3

AEON.WS Hedge Fund Activity: Q1 2022 in Review

50 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q1 2022, worth a combined $6.98M — down 17% from $8.42M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of AEON.WS and 3 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was Parallax Volatility Advisers, adding an estimated $153K. The largest seller was UBS O'Connor, exiting entirely with an estimated $87K sold.

  • 50 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q1 2022, down from 55 in Q4 2021.
  • Funds reported $6.98M of AEON Biopharma Inc stock for Q1 2022, down 17% quarter-over-quarter.
  • 3 funds opened new AEON Biopharma Inc positions in Q1 2022 and 8 closed out, a net change of -5 holders.
  • The largest AEON Biopharma Inc buyer in Q1 2022 was Parallax Volatility Advisers, an estimated $153K added.
  • The largest AEON Biopharma Inc seller in Q1 2022 was UBS O'Connor, an estimated $87K sold.

Based on aggregated 13F filings for Q1 2022.